3313. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
作者: Marcus Maurer.;Luis Felipe Ensina.;Ana Maria Gimenez-Arnau.;Gordon Sussman.;Michihiro Hide.;Sarbjit Saini.;Clive Grattan.;Daria Fomina.;Dimitrios Rigopoulos.;Frederic Berard.;Giorgio Walter Canonica.;Heike Rockmann.;Carla Irani.;Jacek C Szepietowski.;Jeffrey Leflein.;Jonathan A Bernstein.;Jonny G Peter.;Kanokvalai Kulthanan.;Kiran Godse.;Ledit Ardusso.;Olga Ukhanova.;Petra Staubach.;Rodney Sinclair.;Shaila Gogate.;Simon Francis Thomsen.;Tonny Tanus.;Young Min Ye.;Alis Burciu.;Avantika Barve.;Darshna Modi.;Emil Scosyrev.;Eva Hua.;Kerstin Letzelter.;Vineeth Varanasi.;Manmath Patekar.;Thomas Severin.; .
来源: Lancet. 2024年403卷10422期147-159页
Many patients with chronic spontaneous urticaria (CSU) do not achieve complete control of their symptoms with current available treatments. In a dose-finding phase 2b study, ligelizumab improved urticaria symptoms in patients with H1-antihistamine (H1-AH) refractory CSU. Here, we report the efficacy and safety outcomes from two ligelizumab phase 3 studies.
|